Background. Obesity is a risk factor for the progression of chronic kidney disease (CKD). The impact of weight loss on proteinuria and renal function is less clear. We aimed to determine the effect of intentional weight loss on proteinuria and kidney function. Methods. Three bibliographic databases including Medline, Cochrane and SCUPOS as well as reference list of articles were searched. We included randomized and non-randomized controlled trials as well as single-arm trials published in English through May 2009 which examined urinary protein among obese or overweight adults before and after weight loss interventions including dietary restriction, exercise, anti-obesity medications and bariatric surgery. Study characteristics and methodological quality of trials were assessed. Results. Five hundred twenty-two subjects from five controlled and eight uncontrolled trials were included. Weight loss interventions were associated with decreased proteinuria and microalbuminuria by 1.7 g [95% confidence interval (95% CI), 0.7 to 2.6 g] and 14 mg (95% CI, 11 to 17 mg), respectively (P < 0.05). Meta-regression showed that, independent of decline in mean arterial pressure, each 1kg weight loss was associated with 110 mg (95% CI, 60 to 160 mg, P < 0.001) decrease in proteinuria and 1.1 mg (95% CI, 0.5 to 2.4 mg, P = 0.011) decrease in microalbuminuria, respectively. The decrease was observed across different designs and methods of weight loss. Only bariatric surgery resulted in a significant decrease in creatinine clearance. Conclusions. Weight loss is associated with decreased proteinuria and microalbuminuria. There were no data evaluating the durability of this decrease or the effect of weight loss on CKD progression.
Introduction
The World Health Organization officially recognized obesity as a 'global epidemic' in 1997 [1] . In recent years, the growing body of evidence shows a link between obesity and progression of kidney disease [2] [3] [4] . Microalbuminuria is the earliest marker of chronic kidney disease (CKD) and is a predictor of the progression of CKD to end-stage kidney disease [5] . Proteinuria is also an independent risk factor for increased morbidity and mortality from cardiovascular diseases, diabetes, hypertension and end-stage renal diseases (ESRD) [6] . There appears to be a graded association between the severity of obesity and magnitude of microalbuminuria [7] [8] [9] [10] [11] [12] [13] [14] . On the other hand, a decline in urinary protein excretion is associated with metabolic improvement and decreased cardiovascular risks [15] , so that a decline of 50% in urinary protein excretion is shown to be associated with 18% decrease in cardiovascular risks [16] . Therefore, reducing proteinuria is used as a surrogate outcome for evaluating CKD treatment [17] . A relevant question is whether weight loss has a beneficial effect on the reduction of proteinuria and microalbuminuria in obese adults and whether it leads to the decreased rate of progression of CKD and mortality.
In normal subjects, albumin and nitrogen excretion rates as well as endogenous creatinine clearance are functions of the quantity of dietary protein intake [18] . In type 2 diabetes, dietary protein restriction is associated with decreased proteinuria [19] . Although proteinuria is augmented immediately after exercise, the effect of long-term exercise on proteinuria at rest is less clear. Many obese patients are also taking angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers as part of the management of hypertension and diabetic nephropathy [20, 21] . Therefore, it is not clear whether the decrease in proteinuria observed in case reports and cohort studies of intentional weight loss is due to such co-interventions during weight loss or the result of weight loss itself. This systematic review is aimed (i) to determine the effect of weight loss on proteinuria and other markers of renal function, (ii) to compare the effect of different weight loss interventions including protein-restricted diet, caloric-restricted diet, exercise therapy, anti-obesity agents and bariatric surgery on urinary protein and other markers of renal function, (iii) to determine the role of Patient characteristics at baseline on change in severity of proteinuria with weight loss and (iv) to determine the change in the rate of progression of CKD and new cases of ESRD with weight loss.
Materials and methods

Data sources and searches
We searched PubMed, CENTRAL, and SCUPOS for English-language articles, human studies, with age older than 18 from 1985 through May 2009 using the keywords proteinuria; weight loss; anti-obesity agents; exercise; diet, caloric-restricted; diet, fat-restricted; and bariatric surgery as outlined in Appendix 1. We also searched reference lists of relevant articles. The search was performed by two reviewers independently (F.A. and A.E.).
Study selection
We included trials of weight loss interventions that examined the association between weight loss in overweight (Body Mass Index >25 kg/m 2 ) or obese (BMI >30 kg/m 2 ) adults with proteinuria and markers of renal function. They included randomized and non-randomized controlled clinical trials and single-arm trials of weight loss interventions including physical exercise therapy, anti-obesity agents, bariatric surgery and dietary weight loss by restriction of carbohydrate and fat which reported proteinuria or urinary albumin and weight or BMI at baseline and after interventions. We excluded observational studies and those that involved patients with chronic conditions associated with non-intentional weight loss, elite athletes as well as studies with urinary protein measurements within 24 h after exercise. Identified articles were rejected on initial screen if it was determined from the title that they did not address weight loss strategies. When a title could not be rejected with certainty, the full text article was obtained.
Data extraction and quality assessment
Abstraction was performed by one reviewer (F.A.) and independently verified by another (H.I.). The retrieved variables indicated characteristics of studies such as patients' baseline characteristics, inclusion and exclusion criteria, intervention, comparison, outcome and duration of follow-up. Baseline characteristics included age, sex, percentage of patients with diabetes and hypertension, weight or BMI, urinary albumin or protein and glomerular filtration rate (GFR) or creatinine clearance. Interventions were dietary restriction (fat and carbohydrate), exercise, anti-obesity medications and bariatric surgery. Exercise was defined as moderate to intense physical activity with at least 1.8 metabolic equivalents for a minimum duration of 15 min/day for at least 2 days/week for a minimum of 1 month. Anti-obesity agents were defined as any Food and Drug Administrationapproved agents of noradrenergic or selective serotonin reuptake inhibitors approved for weight loss, lipase inhibitors, suppressors of appetite and any other compounds primarily approved for other indications but which have been used in trials to show their anti-obesity effects for a minimum of at least 4 weeks. The primary outcome was change in severity of urinary albumin excretion or proteinuria. In clinical trials, proteinuria is measured as a continuous variable. Secondary outcomes were change in creatinine clearance, change in GFR and change in the rate of progression of CKD. Studies were searched for outcomes according to age, race and sex. For studies with multiple measurements at different time intervals, the last measurement was entered into the analyses. In trials with several arms with different doses of medication, the arm with the highest dose was used for the analyses. Outcome variables including weight and laboratory values were measured at least 12 weeks after the start of interventions. Trials with an intervention period as short as 4 weeks were included only if they had at least a 3-month run-in period prior to interventions to minimize the effect of confounding by acute changes unrelated to true weight loss. The setting was outpatient in all studies. We assessed randomized trials for randomization, allocation concealment and adequacy of blinding. Additionally, we assessed percentage lost to follow-up, intention to treat analysis (where applicable) and generalizability by assessing eligibility criteria. For the cohort studies, percent lost to follow-up and eligibility criteria were evaluated (Table 4) .
Data synthesis and analysis
Data analyses were done by one reviewer (F.A.) and independently verified by another reviewer (S.D.). In studies in which mixed samples of patients with and without proteinuria were recruited, only the subgroups of patients with proteinuria were entered into the analyses if their corresponding data were available. Lazarevic et al. reported individualized data for all patients who had decreased their urinary albumin excretion except for one who did not show a change [22] . For that patient, the baseline mean urinary albumin excretion of the abnormal group was conservatively used at baseline and throughout the follow-up period. In Agrawal's study, the mean and SD of the urinary albumin-creatinine ratio (ACR) were obtained by personal communication with the lead author, while in Stenlof's study where the SD of urinary albumin was not reported [23] , it was estimated by means of SDs from three other similar studies which had the closest characteristics, design and mean of urinary albumin at baseline [11, 24, 25] . Continuous data that were reported as median and range were converted to mean and SD by using the method of Hozo [26] . The measures used in the metaanalysis were the difference between urinary protein or albumin before and after intervention using random effect for weighting method and calculating the I 2 statistics. In controlled clinical trials, the difference between target variables before and after weight loss in the intervention arm was additionally compared with the control arm using pooled SD of pretest values by the method of Morris [27] . Meta-regression using maximum likelihood to estimate the between-study component of variance was applied to assess the relationship between change of weight with change of urinary protein or albumin. Sensitivity analysis and meta-regression were applied to detect the study and the variables contributing to high heterogeneity, respectively. Subgroup analysis was performed in order to explore differences of effect size or direction among different weight loss strategies. Data analysis was with STATA version 10 (College Station, TX, USA). Figure 1 shows the study identification and selection process. Our initial search revealed 450 articles in which 376 were excluded due to not addressing the questions (n = 355), case reports (n = 16) and reviews (n = 5). Of 74 articles retrieved for full text evaluation, 57 were excluded due to not being relevant (n = 39), lack of enough information (n = 11), targeting different populations (n = 3), having BMI less than 25 kg/m 2 (n = 3) and short duration of intervention (n = 1), leaving 13 articles for inclusion [11, [22] [23] [24] [25] [28] [29] [30] [31] [32] [33] [34] [35] . Weight loss and proteinuria 
Results
Trial flow
Study characteristics
There were four randomized and one non-randomized clinical trial and eight prospective cohort interventions including single-arm trials, uncontrolled-arm trials and controlled trials with no follow-up in the control group. Sample size ranged from 8 to 94 patients with a total of 522 subjects followed up between 4 and 104 weeks. The study characteristics are shown in Table 1 . The aim, inclusion and exclusion criteria are summarized in Table 2 . Table 3 shows the summary result of interventions. All trials achieved significant weight loss with intervention. Weight loss, decrease in mean arterial pressure (MAP), proteinuria and albuminuria with active treatment ranged from 2.2 to 58.8 kg, 1.5 to 16 mmHg, 0.03 to 2.5 g and 9 to 333 mg, respectively. Similarly, decrease in GFR and creatinine clearance with active treatment ranged from −15 to 35 and −12 to 21.5 mL/min, respectively. The highest amount of weight loss and decrease in GFR and creatinine clearance was achieved by bariatric surgery. All interventions had methodological limitations ( Table 4) . The percentage of patients with proteinuria or albuminuria at baseline was unclear in four studies [11, 23, 25, 32] , and allocation concealment was unclear in all randomized trials [23, [31] [32] [33] . By design, only one medication-based study could be double blind [23] .
Quantitative data synthesis
Due to the heterogeneity of study populations, studies with gross proteinuria and microalbuminuria are pooled separately.
Outcomes in gross proteinuria
Only Praga, Morales and Saiki [30, 31, 33] had patients with nephrotic range proteinuria. All three studies collected 24-h urine for the measurement of urinary protein excretion and overall showed 3.0 g/day of proteinuria at baseline. While Praga and Saiki used 24-h urine collection to measure creatinine clearance, Morales used the Cockcroft-Gault formula to estimate it [30, 31, 33] . Although Vasquez and Navarro-Diaz [24, 35] also measured proteinuria, because their protein excretion rates were at a micro level, their studies were grouped with those consisting of pa- Weight loss and proteinuriatients with microalbuminuria. Therefore, their measurement of microalbuminuria was used in our analysis. Figure 2 shows the overall effect of weight loss by caloric restriction on the decrease of overt proteinuria. In this pooled analysis, we deleted Solerte's study after sensitivity analysis because of a high heterogeneity it induced for a main effect of 1.46 g [95% confidence interval (95% CI), 0.72 to 2.22 g], I 2 = 68.1% (P = 0.008). Overall, and after sensitivity analysis, dietary restriction-induced weight loss reduced overt proteinuria by 1.7 g (95% CI, 0.7 to 2.6 g), a 55% decrease from baseline (95% CI, 23% to 87%), I 2 = 59.5% (P = 0.08). Meta-regression analysis suggested that this heterogeneity may partially be explained by variation in baseline weight, weight loss and decline of MAP with intervention among different studies ( Table 5 ). The type of study design did not have any impact on the direction of outcome.
Outcomes in microalbuminuria
All other studies had albumin excretion rates below nephrotic range, mostly at microalbuminuria range with an overall mean urinary albumin excretion rate of 26.7 mg/ day at baseline [11, [22] [23] [24] [25] 28, 29, 32, 35] . In the study by Tong [25] , subjects without diabetes had a significantly lower urinary albumin excretion at baseline with a less profound decline in urinary albumin after intervention compared to individuals with diabetes. This discrepancy, along with the use of geometric mean and standard deviation in the study, contributed to a high heterogeneity within this study and between this and other studies. By sensitivity analysis, the non-diabetic arm of this trial contributed to heterogeneity and was, therefore, excluded in subsequent pooled analysis. Only Chagnac measured GFR by priming dose of inulin, p-aminohippuric acid and dextran [11] . In this study, albumin excretion rate was measured from timed urine collection and simultaneous venous blood sampling. The 24-h albumin excretion was estimated from the measured albumin excretion rate. In studies by Lazarevic and Agrawal [22, 29] , the 24-h albumin excretion was estimated from the ACR. All other studies measured urinary microalbuminuria based on a 24-h urine collection. Additionally, Navarro-Diaz and Cubeddu [24, 28] measured creatinine clearance from the 24-h urine collection. In Figure 3 , the overall effect of weight loss interventions on microalbuminuria by type of weight loss intervention is shown. In this analysis, Nicholson's study was eliminated from pooled effect calculation after sensitivity analysis demonstrated that it was an outlier, likely due to its low sample size and very large standard deviation. However, we included it in the meta-regression analysis to investigate sources of heterogeneity. Further sensitivity analysis did not reduce the heterogeneity. Overall, weight loss interventions decreased urinary albumin excretion by 14 mg (95% CI, 11 to 17), a 52% decrease from baseline (95% CI, 40% to 64%), I 2 = 50.0% (P = 0.051). Meta-regression suggested that this heterogeneity may partially be explained by variation of age, duration of follow-up, weight loss and decline in MAP among different studies. The type of study design did not have any impact on the direction of outcome.
Creatinine clearance-GFR outcome
Baseline mean GFR or creatinine clearance in surgical trials was 140.2 mL/min, while it was 88.0 mL/min in non-surgical trials. Figure 4 shows the results of change in creatinine clearance by type of intervention. Accordingly, unlike the pooled non-surgical interventions, surgical interventions decreased GFR or creatinine clearance by 23.7 mL/min (95% CI, 11.4 to 36.2), a 17% decrease from baseline (95% CI, 8% to 26%). Within non-surgical interventions, results were mixed. While Cubeddu showed a decrease in creatinine clearance, Saiki, Morales and Prage did not show any change and Solerte noted an increase in creatinine clearance. 
Subgroup analysis by intervention and baseline characteristics
In overt proteinuria, caloric restriction was associated with a pooled 1.7-g reduction of proteinuria (95% CI, 0.7 to 2.6 g), a 55% decrease from baseline (95% CI, 23% to 87%), while in microalbuminuria, the decrease was 17.5 mg (95% CI, 12.3 to 22.7 mg) or 58% (95% CI, 41% to 76%). Similarly, bariatric surgery was associated with 13 mg (95% CI, 5 to 21 mg) or a 92% decrease (95% CI, 35% to 149%), medications with 15 mg (95% CI, 13 to 18 mg) or a 28% decrease (95% CI, 24% to 34%), exercise with 30 mg (95% CI, −3 to 61 mg) or a 49% decrease (95% CI, −5% to 100%) and lifestyle modification with 9 mg (95% CI, 5 to 13 mg) or a 62% decrease (95% CI, 34% to 89%) in albumin excretion rate. No study analysed the change in urinary protein excretion by subgroups of age, sex and other demographic characteristics. No study addressed the change in the rate of progression of CKD or durability of reduced urinary protein excretion. Table 5 presents the results of meta-regression. Accordingly, decrease in overt proteinuria was correlated with weight loss, decline in MAP and weight at baseline (P < 0.05). Each 1 kg decrease in weight was associated with 110 mg (95% CI, 60 to 160 mg, P < 0.001) or a 4% decrease (95% CI, 2% to 5%) in urinary protein excretion, independent of decline in MAP and baseline weight. Similar results were observed after adjusting for the use of ACEI. Decrease of microalbuminuria was also directly correlated with weight loss, duration of intervention and decline of MAP, but was inversely correlated with age, so that each 1 kg weight loss was associated with 1.1 mg (95% CI, 0.5 to 2.4 mg, P = 0.011) or a 4% decrease (95% CI, 2% to 9%) of microalbuminuria independent of decline of MAP and each 1 week of weight loss intervention was associated with 0.7 mg decrease in microalbuminuria (95% CI, 0.3 to 1.2 mg, P = 0.003). Creatinine clearance and GFR were directly correlated with change of body weight.
Meta-regression analysis
Discussion
Weight loss in overweight and obese adults with mild to moderate CKD results in a significant decrease in proteinuria and albuminuria, regardless of study designs and methods of weight loss. All trials had methodological limitations including low sample size, short period of followup and lack of control groups in uncontrolled trials. In a population-based observation, Bello et al. reported parallel changes in albuminuria with change in weight [36] . This observation had a mean follow-up of 4.2 years and did not differentiate intentional from unintentional Weight loss and proteinuriaweight loss, raising the possibility of natural course effect of cachexia-inflammation of chronic illnesses. In our reviewed articles, the duration of follow-up and intervention is much lower than Bello's report and, therefore, it is a remote possibility that the decline in body weight achieved after interventions for intentional weight loss in a relatively short period of time is a consequence of such an effect. Consistent pattern of decline of urinary protein among different study designs suggests that the decrease could be beyond regression to the mean and may better be explained by weight loss interventions. In spite of consistency in the direction of outcome, it is our assessment that the quality of evidence for the beneficial effect of weight loss on decreasing proteinuria or albuminuria is moderate. The potential mechanisms of early renal injury are suspected to be hyperfiltration and excess excretory load with increase in GFR, renal plasma flow, glomerular pressure and filtration fraction, partially mediated by increased renal sodium reabsorption, increased renal sympathetic activity and activation of renin-angiotensin system [37] [38] [39] , lipotoxicity with intracellular lipid overload and shunt of excess fatty acids toward synthesis of lipid products [40, 41] and finally through increased inflammation and oxidative stress [42, 43] . Therefore, the beneficial effect of weight loss on renal function may be through the decrease in hyperfiltration, lipotoxicity, inflammation and oxidative stress. The most profound decrease in GFR and creatinine clearance has only been achieved by bariatric surgery. Highest baseline weight, GFR and creatinine clearance in patients of surgical trials compared to other studies suggest the highest hyperfiltration in the former which is reversed by the most profound weight loss. The reduction of GFR by weight loss may be interpreted as another beneficial effect of intervention by change in the status of hyperfiltration; however, no trial has been able to capture any change in the rate of progression of CKD within a study period. Non-surgical trials which did not achieve such a decrease in GFR, neither achieved this level of weight loss nor had considerably higher weight, GFR or creatinine clearance at baseline. Patients in surgical trials were also generally healthier compared to Saiki and Solerte's study in which individuals had overt nephropathy. These differences in baseline characteristics along with probable differences in intensity of interventions among non-surgical trials are likely explanations of the mixed effect of weight loss intervention on renal function among different trials. Direct correlation between changes of proteinuria with body weight suggests that the higher categories of body weight may get the most benefit from weight loss programmes. Association of decline in proteinuria with decrease of MAP, independent of weight loss, firstly suggests that the effect of decrease in proteinuria is not completely a consequence of decline in blood pressure and secondly it underscores the possibility of achieving maximum benefits upon combining weight loss programmes with pharmacologic control of blood pressure. In microalbuminuria, the association between duration of weight loss intervention and maintenance of weight loss with decrease of albumin excretion may be a reflection of longer duration of follow-up with trials of microalbuminuria compared to those with overt proteinuria, allowing to capture such an effect which highlights the benefit of maintenance of weight loss. Inverse correlation between levels of decline of urinary albumin excretion with age underscores the importance of obesity prevention programmes earlier in the course of CKD and at younger age.
Albuminuria is an independent risk factor for increased cardiovascular mortality and morbidity both in diabetic and non-diabetic patient populations [44] [45] [46] . On the other hand, a decline in urinary protein excretion is shown to be associated with a significant decrease in cardiovascular risks and events [15, 47] . Therefore, albuminuria is not only a surrogate marker of increased mortality and morbidity but also viewed as a therapeutic target [16, 17] and, therefore, any attempt for its decline may have beneficial effects. Unintentional weight loss as observed in advanced stages of chronic illnesses such as end-stage kidney diseases, advanced heart failure or old age may be a reflection of cachexia-inflammatory status of the chronic illness and often is highly associated with mortality. However, the increased mortality in such entities are often reported through observational studies which have not been able to distinguish intentional from unintentional weight loss or ignored adequate adjustments by chronicity or severity of underlying illnesses [48] [49] [50] [51] , sending controversial massages about the benefits of intentional weight loss. The patients in trials of this review are also categorized as mild to moderate kidney failure without heart failure. Therefore, future clinical trials are needed to find the optimal clinical status in chronic illnesses such as end-stage kidney disease or heart failure in which intentional weight loss would still provide benefit. Future adequately powered trials should also focus on hard clinical endpoints such as mortality or progression of CKD with adequate follow-ups and plans for maintenance of body weight after weight loss.
There are several limitations in our review. The patient populations of different studies are heterogeneous and at different stages of disease. To overcome this, two strategies were approached. Firstly, studies with similar patient populations and severity of disease at baseline were pooled together. This is shown by analyses of patients with gross proteinuria and microalbuminuria separately. Secondly, Weight loss and proteinuriawithin each category of studies with similar kidney function, meta-regression analysis was applied to further investigate the sources of heterogeneity including variability in baseline characteristics. Other limitations are low sample size of studies, open-label nature of interventions, short duration of follow-up and inability to detect change in the trend of progression of CKD which probably needs much larger sample size, longer follow-up and maintenance of weight loss. The non-randomized and uncontrolled follow-up interventions have more methodological limitations due to lack of control group providing low-quality evidence for the decrease of urinary protein. The followup has also a wide range in different trials, but we addressed the effect of duration of follow-up in meta-regression analysis. The amount of decline in proteinuria with each 1 kg weight loss is likely underestimated by our conservative analytic approach as well as the heterogeneity in the follow-up period. Additionally, in surgical trials, not all patients had microalbuminuria at baseline (surgical indication). Therefore, the presence of a significant proportion of patients with normal range microalbuminuria at baseline has contributed to an underestimation of effect of size by diluting the net pooled effect in the total number of patients. Also, data about the influence of weight on GFR is scarce. On the other hand, the indirect method of estimating GFR such as using creatinine clearance or its calculation by Cockcroft formula can have increased margins of error in obesity which likely has contaminated our results. The generalizability of beneficiary effect of weight loss on urinary protein excretion is also limited to a subgroup of relatively healthy patients with mild to moderate CKD and no history of congestive heart failure.
Conclusion
In conclusion, evidence supports the beneficiary effect of weight loss on the surrogate outcomes of the decrease of urinary protein excretion. There are no data on the effect of weight loss on the progression to CKD. Further research is required to determine the impact of weight loss on clinical renal outcomes.
